This method ensures sequential mutation of p53 following tumour initiation by oncogenic Kras. From eight KrasLA2,Rosa26-CreERT2/KrasWT; MADM-p53 mice dissected following the development of tumour-related morbidity, we observed two fluorescently labelled tumours on whole mount analysis (Fig. 3b). The gene discussed is KRAS; the disease is neoplasm.